D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Improvement of Hemodialysis Catheter Function: TROPICS 3
James A. Tumlin,Jesse Goldman,David Spiegel,David Roer,K. Adu Ntoso,Martha Blaney,Joan R. Jacobs,Barbara S. Gillespie,Susan M. Begelman +8 more
TL;DR: Tenecteplase improved HD catheter function and had a favorable safety profile compared with placebo, and restored blood flow rates in dysfunctional HD catheters.
Journal ArticleDOI
A review of acute stress reactions among victims of violence
TL;DR: In this paper, a review of the literature pertaining to the psychological trauma occurring in the immediate aftermath of interpersonal violence is presented. But, the limited amount of research conducted on treatment interventions on acute stress reactions to violence indicates that there is not one best intervention.
Book ChapterDOI
Psychosocial interventions in cancer: Group therapy techniques.
David Spiegel,Susan Diamond +1 more
Journal ArticleDOI
Topics in Global Public Health
David Spiegel,Richard A. Gosselin,Richard A. Gosselin,R. Richard Coughlin,R. Richard Coughlin,Adam L. Kushner,Stephen B. Bickler +6 more
TL;DR: The goal of this review is to familiarize the orthopaedic surgeon with selected topics in public health, including health systems, burden of disease, disability adjusted life year (DALY), cost-effective analysis, and related concepts (eg, met versus unmet need, access, utilization, effective coverage).
Patent
Tlr-agonist-conjugated antibody recruiting molecules (tlr-arms)
TL;DR: In this paper, a chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized Prostate Cancer cells, were described.